These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37296596)
1. XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer. Huang MY; Huang YJ; Cheng TL; Jhang WY; Ke CC; Chen YT; Kuo SH; Lin IL; Huang YH; Chuang CH Cells; 2023 May; 12(11):. PubMed ID: 37296596 [TBL] [Abstract][Full Text] [Related]
2. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy. Li S; Zhu L; Yao L; Xia L; Pan L BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226 [TBL] [Abstract][Full Text] [Related]
8. [The efficacy and side effects of rigosertib combined with chemotherapy in Zhang HC; Zhou XY; Fu DL; Ding YW; Xiao Q; Yuan Y Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):138-145. PubMed ID: 36781234 [No Abstract] [Full Text] [Related]
9. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883 [TBL] [Abstract][Full Text] [Related]
10. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096 [TBL] [Abstract][Full Text] [Related]
11. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713 [TBL] [Abstract][Full Text] [Related]
12. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Carraro S; Roca EL; Cartelli C; Rafailovici L; Castillo Odena S; Wasserman E; Gualdrini U; Huertas E; Barugel M; Ballarino G; Rodriguez MC; Masciangioli G Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):397-402. PubMed ID: 12243813 [TBL] [Abstract][Full Text] [Related]
13. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186 [TBL] [Abstract][Full Text] [Related]
14. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351 [TBL] [Abstract][Full Text] [Related]
15. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017 [TBL] [Abstract][Full Text] [Related]
16. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208 [TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Simpson D; Dunn C; Curran M; Goa KL Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525 [TBL] [Abstract][Full Text] [Related]
18. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319 [TBL] [Abstract][Full Text] [Related]
19. Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation. Pangeni R; Choi SW; Jeon OC; Byun Y; Park JW Int J Nanomedicine; 2016; 11():6379-6399. PubMed ID: 27942212 [TBL] [Abstract][Full Text] [Related]
20. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]